CVD risk, prevention and implementation

Current recommended preventive treatment with blood pressure- and lipid-lowering medications can more than halve the risk of future CVD events. However, our findings showed that >70% of those at high CVD risk in Australia are not receiving such therapies. Over the next 5 years we will work with policy and practice partners to: (i) leverage data on current world-wide best CVD practice and risk, through international collaborators; (ii) quantify CVD risk in relation to common potentially modifiable factors, including treatment (iii) provide robust data on implementation gaps and their health and economic consequences; (iv) develop and rigorously research interventions to enable improved prevention and treatment, through policy and primary care. A focus will be implementation in relation to absolute CVD risk assessment and management, interfacing with work on variation to target underserved groups.

 

Members

Professor Emily Banks

Dr Grace Joshy 

Dr Rosemary Korda

Kay Soga

Dr Cathy Day

Dr Ellie Paige

Jenny Welsh

Jason Agostino 

Updated:  20 September 2017/Responsible Officer:  Director/Page Contact:  Webmaster